In-Patient Study In Schizophrenic Patients

A Placebo Controlled, Double-Blind, Randomised Study Investigating the Safety, Tolerability and Pharmacokinetics of Ascending Multiple Oral Doses of SB-773812 in Male and Female Schizophrenic Patients for up to 28 Days

This study is a placebo-controlled study to assess the safety and tolerability of a novel antipsychotic medication, (773812) when given to schizophrenic patients for twenty-eight days. Assessments include blood sampling to determine drug concentrations, psychiatric assessments while under treatment, and movement assessments to evaluate potential side effects.

Inclusion Criteria:

• Must have schizophrenia that has been stable for at least three months.
• Willing to discontinue current anti-psychotic medications (under supervision) prior to the study.
• Willing to live at the study center for a total of 38 days and then return for three follow-up visits.

Exclusion Criteria:

• Taking medications for conditions other than schizophrenia.
• History of alcohol or drug abuse within six months of the study, and their alcohol consumption must meet moderate guidelines.